NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 28.1% and is now trading at $11.54. View which stocks have been most impacted by Coronavirus.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its quarterly earnings results on Thursday, May, 7th. The company reported $0.76 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.59 by $0.17. The company earned $4.36 billion during the quarter, compared to the consensus estimate of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. The business's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

22 Wall Street analysts have issued 12 month target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $11.50 in the next year. This suggests that the stock has a possible downside of 0.3%. View analysts' price targets for Teva Pharmaceutical Industries.

News headlines about TEVA stock have been trending negative recently, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT) and Catalent (CTLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.54.

Teva Pharmaceutical Industries has a market capitalization of $12.60 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]